531599 Stock Overview
FDC Limited manufactures and markets pharmaceutical products in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 531599 from our risk checks.
FDC Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹440.05 |
| 52 Week High | ₹487.50 |
| 52 Week Low | ₹281.40 |
| Beta | 0.22 |
| 1 Month Change | -2.41% |
| 3 Month Change | -1.23% |
| 1 Year Change | 47.05% |
| 3 Year Change | 31.48% |
| 5 Year Change | 167.02% |
| Change since IPO | 10,193.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| 531599 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.0% | -3.4% | -3.7% |
| 1Y | 47.1% | 53.6% | 38.4% |
Return vs Industry: 531599 underperformed the Indian Pharmaceuticals industry which returned 53.6% over the past year.
Return vs Market: 531599 exceeded the Indian Market which returned 38.4% over the past year.
Price Volatility
| 531599 volatility | |
|---|---|
| 531599 Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 531599 has not had significant price volatility in the past 3 months.
Volatility Over Time: 531599's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1936 | 6,372 | Nandan Chandavarkar | www.fdcindia.com |
FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, analgesics, and others; and oral rehydration salts. It provides specialized formulations primarily under the Zifi, Ziglim Plus 2, Vitcofol, Pyrimon DF, Zocon, Zoxan, Zathrin, Zipod, Amodep-AT, Zefu, Cotaryl, and Mycoderm brand names.
FDC Limited Fundamentals Summary
| 531599 fundamental statistics | |
|---|---|
| Market cap | ₹72.40b |
| Earnings (TTM) | ₹2.90b |
| Revenue (TTM) | ₹19.16b |
24.7x
P/E Ratio3.7x
P/S RatioIs 531599 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 531599 income statement (TTM) | |
|---|---|
| Revenue | ₹19.16b |
| Cost of Revenue | ₹6.90b |
| Gross Profit | ₹12.26b |
| Other Expenses | ₹9.36b |
| Earnings | ₹2.90b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 29, 2024
| Earnings per share (EPS) | 17.79 |
| Gross Margin | 63.97% |
| Net Profit Margin | 15.12% |
| Debt/Equity Ratio | 1.2% |
How did 531599 perform over the long term?
See historical performance and comparison